589 related articles for article (PubMed ID: 30118334)
1. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
Le D; Gelmon KA
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):833-839. PubMed ID: 30118334
[TBL] [Abstract][Full Text] [Related]
2. Olaparib for the treatment of breast cancer.
Griguolo G; Dieci MV; Guarneri V; Conte P
Expert Rev Anticancer Ther; 2018 Jun; 18(6):519-530. PubMed ID: 29582690
[TBL] [Abstract][Full Text] [Related]
3. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Robson ME; Tung N; Conte P; Im SA; Senkus E; Xu B; Masuda N; Delaloge S; Li W; Armstrong A; Wu W; Goessl C; Runswick S; Domchek SM
Ann Oncol; 2019 Apr; 30(4):558-566. PubMed ID: 30689707
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
Lee CK; Scott C; Lindeman GJ; Hamilton A; Lieschke E; Gibbs E; Asher R; Badger H; Paterson R; Macnab L; Kwan EM; Francis PA; Boyle F; Friedlander M
Br J Cancer; 2019 Feb; 120(3):279-285. PubMed ID: 30655615
[TBL] [Abstract][Full Text] [Related]
6. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
7. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
[TBL] [Abstract][Full Text] [Related]
8. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
9. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Robson M; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Delaloge S; Li W; Tung N; Armstrong A; Wu W; Goessl C; Runswick S; Conte P
N Engl J Med; 2017 Aug; 377(6):523-533. PubMed ID: 28578601
[TBL] [Abstract][Full Text] [Related]
10. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
12. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
13. Olaparib for the treatment of breast cancer.
Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
[TBL] [Abstract][Full Text] [Related]
14. Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer.
McCrea C; Hettle R; Gulati P; Taneja A; Rajora P
J Comp Eff Res; 2021 Sep; 10(13):1021-1030. PubMed ID: 34231369
[No Abstract] [Full Text] [Related]
15. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
Im SA; Xu B; Li W; Robson M; Ouyang Q; Yeh DC; Iwata H; Park YH; Sohn JH; Tseng LM; Goessl C; Wu W; Masuda N
Sci Rep; 2020 May; 10(1):8753. PubMed ID: 32472001
[TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J; Fasching PA; Couch FJ; Delaloge S; Labidi-Galy I; O'Shaughnessy J; Park YH; Eisen AF; You B; Bourgeois H; Gonçalves A; Kemp Z; Swampillai A; Jankowski T; Sohn JH; Poddubskaya E; Mukhametshina G; Aksoy S; Timcheva CV; Park-Simon TW; Antón-Torres A; John E; Baria K; Gibson I; Gelmon KA;
Breast Cancer Res Treat; 2024 Apr; 204(2):237-248. PubMed ID: 38112922
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
Hammel P; Kindler HL; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Joo S; Yoo HK; Patel N; Golan T;
Ann Oncol; 2019 Dec; 30(12):1959-1968. PubMed ID: 31562758
[TBL] [Abstract][Full Text] [Related]
19. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
[TBL] [Abstract][Full Text] [Related]
20. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]